Cantargia publishes interim report for third quarter of 2018
Cantargia AB’s interim report for the third quarter of 2018 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the third quarter Clinical · In August, Cantargia presented an update on its CANFOUR clinical trial and phase IIa preparations. Patents · In July, Cantargia received preliminary approval from EPO for its application for expanded patent protection in respect of the treatment of solid tumours. · In July, Cantargia’s patent application for its CAN04 (nidanilimab) antibody was approved in China. · In